PCR was used to isolate nucleotide sequences that may encode novel members of the neuropeptide Y receptor family. By use of a PCR product as a hybridization probe, a full-length human cDNA was isolated that encodes a 375-aa protein with a predicted membrane topology identifying it as a member of the G-protein-coupled receptor superfamily. After stable transfection of the cDNA into human embryonic kidney 293 cells, the receptor exhibited high affinity (Kd = 2.8 nM) for 1251-labeled human pancreatic polypeptide (PP).Competition binding studies in whole cells indicated the following rank order of potency: human PP = bovine PP 2 human [Pro34] peptide YY > rat PP > human peptide VY = human neuropeptide Y. Northern blot analysis revealed that human PP receptor mRNA is most abundantly expressed in skeletal muscle and, to a lesser extent, in lung and brain tissue. A rat cDNA clone encoding a high-affinity PP receptor that is 74% identical to the human PP receptor at the amino acid level was also isolated. These receptor clones will be useful in elucidating the functional role of PP and designing selective PP receptor agonists and antagonists.Pancreatic polypeptide (PP), peptide YY (PYY), and neuropeptide Y (NPY) are C-terminal amidated, 36-aa peptides that constitute the mammalian NPY family (1). PP is produced predominantly by pancreatic islet cells and regulates pancreatic exocrine secretion through a mechanism that is not fully understood but may involve inhibition of vagal input to the pancreas (2, 3). PYY-like immunoreactivity is found in endocrine cells of the lower gastrointestinal tract, and the peptide has been shown to have a variety of effects on gastrointestinal function (4, 5). NPY, which is the most highly conserved of the family members between species (6), is extensively distributed throughout both the central and the peripheral nervous systems (7,8). NPY is colocalized with norepinephrine in postganglionic sympathetic nerves (4) and is a potent vasopressor agent (9). The observations of persistent vasoconstriction after a-adrenergic receptor blockade (10, 11) and elevated levels of NPY in hypertensive patients (10, 12) suggest a possible role for NPY in the pathophysiology of hypertension. In the central nervous system, NPY immunoreactivity and mRNA are prevalent in various hypothalamic nuclei, the cerebral cortex, and the septal-hippocampal system and striatum (5). Important effects of centrally administered NPY include hyperphagia (13), anxiolysis (14), and regulation of pituitary hormone release (15).Receptors for NPY/PYY have been delineated on the basis of pharmacological selectivity exhibited by certain tissues and cell lines. The Y1 receptor exhibits high affinity for NPY, PYY, and C-terminal-substituted variants, including [Leu3t,Pro34]NPY, but low affinity for long C-terminal fragments such as 17). This receptor, which is a member of the G-protein-coupled receptor superfamily, has been cloned (18), and its pharmacological properties in transfected cells are identical to those of Y1 rece...